Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xilio Therapeutics, Inc. on March 12, 2026. The report details a material corporate action involving a reverse stock split intended to maintain the company's listing on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and capital structure event.
Material Changes
- Reverse Stock Split: A 1-for-14 reverse stock split of the Company's common stock was effected as of 5:00 p.m. Eastern Time on March 13, 2026.
- Share Reclassification: Every fourteen shares of issued and outstanding Common Stock were automatically reclassified and combined into one share.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
- Trading Details: Common stock began trading on a post-split basis on March 16, 2026, under the existing symbol "XLO" with a new CUSIP number (28422T209).
- Equity Adjustments: Proportionate adjustments were made to shares available under equity incentive plans and the exercise prices of outstanding equity awards.
Guidance, Outlook, and Risks
The primary objective of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The filing includes a cautionary note regarding forward-looking statements, highlighting risks related to the company's ability to comply with listing standards and the timing of the split. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the new CUSIP number (28422T209) for post-split trading.
- Confirm the cash payment received for any fractional shares resulting from the 1-for-14 split.
- Review the adjusted exercise prices and share counts for any outstanding equity awards or options.
- Monitor the stock price on March 16, 2026, to ensure compliance with Nasdaq minimum bid price requirements.